Lancet
-
Randomized Controlled Trial Multicenter Study Comparative Study
Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
Antibodies targeting interleukin (IL)-23 and IL-17A effectively treat moderate-to-severe psoriasis. ECLIPSE is the first comparator study of an IL-23p19 inhibitor, guselkumab, versus an IL-17A inhibitor, secukinumab. The primary objective of this study was to show superiority of clinical response at week 48 for guselkumab versus secukinumab. ⋯ This study was funded by Janssen Research & Development.
-
Biography Historical Article
Helen Brooke Taussig: preserver of babies' hearts and limbs.